These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26769912)

  • 1. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Groot PF; Ruhé HG; Barkhof F; Diamant M; Ijzerman RG
    J Endocrinol; 2016 Apr; 229(1):1-12. PubMed ID: 26769912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.
    van Bloemendaal L; Veltman DJ; Ten Kulve JS; Groot PF; Ruhé HG; Barkhof F; Sloan JH; Diamant M; Ijzerman RG
    Diabetes Obes Metab; 2015 Sep; 17(9):878-86. PubMed ID: 26094857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.
    ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Deacon CF; Holst JJ; Konrad RJ; Sloan JH; Drent ML; Diamant M; IJzerman RG
    Diabetologia; 2015 Dec; 58(12):2688-98. PubMed ID: 26385462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.
    Ten Kulve JS; Veltman DJ; Gerdes VEA; van Bloemendaal L; Barkhof F; Deacon CF; Holst JJ; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2017 Nov; 40(11):1522-1529. PubMed ID: 29025878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.
    van Ruiten CC; Ten Kulve JS; van Bloemendaal L; Nieuwdorp M; Veltman DJ; IJzerman RG
    Psychoneuroendocrinology; 2022 Mar; 137():105667. PubMed ID: 35033928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
    van Bloemendaal L; IJzerman RG; Ten Kulve JS; Barkhof F; Konrad RJ; Drent ML; Veltman DJ; Diamant M
    Diabetes; 2014 Dec; 63(12):4186-96. PubMed ID: 25071023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.
    Bae JH; Choi HJ; Cho KIK; Kim LK; Kwon JS; Cho YM
    Diabetes Metab J; 2020 Apr; 44(2):248-259. PubMed ID: 31701698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats.
    Cao X; Zhou X; Liu XM; Zhou LH
    J Mol Endocrinol; 2016 Jul; 57(1):13-21. PubMed ID: 27151572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
    Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
    Daousi C; Pinkney JH; Cleator J; Wilding JP; Ranganath LR
    Regul Pept; 2013 May; 183():54-61. PubMed ID: 23499806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2.
    Baldassano S; Bellanca AL; Serio R; Mulè F
    J Endocrinol; 2012 Jun; 213(3):277-84. PubMed ID: 22457516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy.
    Meyer-Gerspach AC; Ly HG; Borgwardt S; Dupont P; Beglinger C; Van Oudenhove L; Wölnerhanssen BK
    Diabetes Obes Metab; 2018 Oct; 20(10):2330-2338. PubMed ID: 29790260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA
    Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.
    Ng NBH; Low YW; Rajgor DD; Low JM; Lim YY; Loke KY; Lee YS
    Clin Endocrinol (Oxf); 2022 Feb; 96(2):144-154. PubMed ID: 34448208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.